Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus

BACKGROUND: For programmed cell death protein 1/programmed death-ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC), the addition of immune checkpoint inhibitors (ICIs) to chemotherapy has been shown to increase the objective response rate (ORR) by only 13.4–16.3%. Thus, examining conver...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Jing, Ma, Xuqian, Chen, Xin, Feng, Mingqian, Jin, Xin, Wang, Ke, Wan, Jixi, Zhu, Xianmin, Xie, Rong, Dong, Shuang, Hu, Sheng, Jiang, Hui, Xie, Conghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372655/
https://www.ncbi.nlm.nih.gov/pubmed/35965796
http://dx.doi.org/10.21037/atm-22-3423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372655/
https://www.ncbi.nlm.nih.gov/pubmed/35965796
http://dx.doi.org/10.21037/atm-22-3423

Ejemplares similares